Ameliorative effect of Rosuvastatin on Hepatic Tissue in Rat Model Exposed to Methotrexate Rosuvastatin effects on Hepatic Tissue in Rat Model Exposed to Methotrexate
Article Sidebar
Main Article Content
Abstract
The research aims to examine the therapeutic effect of rosuvastatin (RSV) on methotrexate (MTX)- induced liver toxicity, focusing on tissue integrity and oxidative damage. For this aim, 30 adult albino-type male rats were categorized into 3 groups of 10 rats each: normal control, MTX-treated, and MTX+RSV-treated. Intraperitoneal administration of 20 mg/kg MTX was utilised to induce liver toxicity in MTX-treated and MTX+ RSV -treated groups on day 1. Following induction, MTX+ RSV -treated rats were orally delivered RCV at 20 mg/kg as a therapeutic intervention for one week. The therapeutic duration was contingent upon prior research. Histopathological and biochemical parameters, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), were assessed, along with the expression of oxidative stress indicators (malondialdehyde (MDA) and reduced glutathione (GSH)) in hepatic tissue. Results revealed that RSV markedly reduced the severity of MTX-induced hepatic injury by attenuating elevations in hepatic biochemical markers, including ALT and AST, and simultaneously rectifying histological abnormalities. Moreover, RSV therapy in MTX-exposed rats markedly decreased oxidative stress markers, including MDA, while increasing the level of antioxidative molecules, notably GSH, in hepatic tissues. The study concluded that RSV may help against MTX-provoked hepatic injury, due to its robust antioxidant and anti-inflammatory properties.
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The Journal of Medical and Oral Biosciences uses a Creative Commons Attribution (CC Attribution-ShareAlike 4.0) and its license of (CC BY-SA 4.0). This license allows the authors to hold ownership of the copyright of their articles.
Attribution-Share Alike 4.0 International License (CC BY-SA 4.0). 
Under the CC BY-SA 4.0 the authors are free to:
Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
No use, distribution or reproduction is permitted which does not comply with these terms.
https://creativecommons.org/licenses/by-sa/4.0/
References
1. Babai S, Auclert L, Le-Louët H. Safety data and withdrawal of hepatotoxic drugs.
Therapie. 2021 Nov-Dec;76(6):715-723. doi: 10.1016/j.therap.2018.02.004.
Epub 2018 Feb 21. PMID: 29609830.
2. Björnsson H, Björnsson E. Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management. Eur J Intern Med. 2022;97:26-31. doi: 10.1016/j.ejim.2021.10.035. Epub 2021 Nov 9. PMID: 34772600
3. Saravanan V, Kelly C. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology. 2004;43(2):143-7. doi: 10.1093/rheumatology/keg466. Epub 2003 Aug 15. PMID: 12923285
4. Al-Refai A, Ali A, Kamal K. Immunohistochemical study of the effect of green tea extract on methotrexate-induced oral mucositis in albino rats. J Cytol Histol. 2014;5(3):1-7. doi.org/10.4172/2157-7099.1000227
5. Ezhilarasan D. Hepatotoxic potentials of methotrexate: Understanding the possible toxicological molecular mechanisms. Toxicology. Doi: 2021;458:152840. 10.1016/j.tox.2021.152840. Epub 2021 Jun 24. PMID: 34175381.
6. Oda H, Keane WF. Recent advances in statins and the kidney. Kidney Int. 1999;56:S2-S5. doi: 10.1046/j.1523-1755.1999.07101.x. PMID: 10412725
7. Aljawad FH, Hashim HM, Jasim GA, Kadhim HM, Gorgi AQ, Jawad RF. Effects of atorvastatin and coenzyme Q10 on glycemic control and lipid profile in type 2 diabetic patients. Int J Pharm Sci Rev Res. 2015;34(2):183-6.
8. ATTARBASHEE RK. The antitoxic effect of the rosuvastatin in the cyclophosphamide-induced liver toxicity in male rats. Assiut Veterinary Medical Journal. 2025;71(185):187-203.
9. Abdel-Daim MM, Abdeen A. Protective effects of rosuvastatin and vitamin E against fipronil-mediated oxidative damage and apoptosis in rat liver and kidney. Food Chem Toxicol. 2018;114:69-77. doi: 10.1016/j.fct.2018.01.055. Epub 2018 Feb 9. PMID: 29432839
10. Arulpriya P, Lalitha P, Hemalatha S. Antimicrobial testing of the extracts of Samanea saman (Jacq.) Merr. 2010.
11. Yamagata T, Kinoshita K, Nozaki Y, Sugiyama M, Ikoma S, Funauchi M. Effects of pravastatin in murine collagen-induced arthritis. Rheumatol Int. 2007;27(7):631-9. doi: 10.1007/s00296-006-0270-9. Epub 2006 Nov 21. PMID: 17119970
12. Hamzeh M, Hosseinimehr SJ, Khalatbary AR, Mohammadi HR, Dashti A, Amiri FT. Atorvastatin mitigates cyclophosphamide-induced hepatotoxicity via suppression of oxidative stress and apoptosis in rat model. Res Pharm Sci. 2018;13(5):440-9. doi: 10.4103/1735-5362.236837. PMID: 30271446
13. Attarbashee R. The antitoxic effect of the rosuvastatin in the cyclophosphamide-induced liver toxicity in male rats. Assiut Vet Med J 71: 187–203. 2025.
14. Center SA. Interpretation of liver enzymes. Vet Clin North Am Small Anim Pract. 2007;37(2):297-333. doi: 10.1016/j.cvsm.2006.11.009. PMID: 17336677.
15. McGill MR. The past and present of serum aminotransferases and the future of liver injury biomarkers. EXCLI journal. 2016;15:817. doi: 10.17179/excli2016-800. eCollection 2016. PMID: 28337112 PMCID: PMC5318690
16. Şener G, Ekşioğlu-Demiralp E, Cetiner M, Ercan F, Şirvancı S, Gedik N, et al. L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Cell Biol Toxicol. 2006;22(1):47-60. doi: 10.1007/s10565-006-0025-0. PMID: 16463019
17. Uraz S, Tahan V, Aygun C, Eren F, Unluguzel G, Yuksel M, et al. Role of ursodeoxycholic acid in prevention of methotrexate-induced liver toxicity. Dig Dis Sci. 2008;53(4):1071-7. doi: 10.1007/s10620-007-9949-3. Epub 2007 Oct 13. PMID: 17934844.
18. Bedoui Y, Guillot X, Sélambarom J, Guiraud P, Giry C, Jaffar-Bandjee MC, et al. Methotrexate an old drug with new tricks. Int J Mol Sci. 2019;20(20):5023. doi: 10.3390/ijms20205023. PMID: 31658782 PMCID: PMC6834162
19. Jahovic N, Çevik H, Şehirli AÖ, Yeğen BÇ, Şener G. Melatonin prevents methotrexate‐induced hepatorenal oxidative injury in rats. Journal of pineal research. 2003;34(4):282-7. doi.org/10.1034/j.1600-079X.2003.00043.x PMID: 12662351
20. Dalaklioglu S, Genc G, Aksoy N, Akçit F, Gumuslu S. Resveratrol ameliorates methotrexate-induced hepatotoxicity in rats via inhibition of lipid peroxidation. Hum Exp Toxicol. 2013;32(6):662-71. doi: 10.1177/0960327112468178. Epub 2013 Feb 19. PMID: 23424212
21. Ozougwu JC. The role of reactive oxygen species and antioxidants in oxidative stress. International Journal of Research. 2016;1(8):1-8. doi: 10.1155/2016/3164734. PMCID: PMC4736974 PMID: 26881021
22. Ighodaro O, Akinloye O. First line defence antioxidants-superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): Their fundamental role in the entire antioxidant defence grid. Alexandria journal of medicine. 2018;54(4):287-93. doi.org/10.1016/j.ajme.2017.09.001
23. Tabassum H, Parvez S, Pasha ST, Banerjee BD, Raisuddin S. Protective effect of lipoic acid against methotrexate-induced oxidative stress in liver mitochondria. Food Chem Toxicol. 2010;48(7):1973-9. doi: 10.1016/j.fct.2010.04.047. Epub 2010 May 6. PMID: 20451574.
24. Jahovic N, Şener G, Çevik H, Ersoy Y, Arbak S, Yeğen BÇ. Amelioration of methotrexate‐induced enteritis by melatonin in rats. Cell Biochemistry and Function: Cellular biochemistry and its modulation by active agents or disease. 2004;22(3):169-78. doi: 10.1002/cbf.1071. PMID: 15124182.
25. Aithal GP. Hepatotoxicity related to antirheumatic drugs. Nature Reviews Rheumatology. 2011;7(3):139-50. doi: 10.1038/nrrheum.2010.214. Epub 2011 Jan 25. PMID: 21263458
26. Hadi NR, Al-Amran FG, Swadi A. Metformin ameliorates methotrexate-induced hepatotoxicity. Journal of Pharmacology and Pharmacotherapeutics. 2012;3(3):248-53. doi: 10.4103/0976-500X.99426. PMID: 23129960
27. Taysi S, Algburi FS, Taysi ME, Caglayan C. Caffeic acid phenethyl ester: A review on its pharmacological importance, and its association with free radicals, COVID‐19, and radiotherapy. Phytother Res. 2023;37(3):1115-35. doi: 10.1002/ptr.7707. Epub 2022 Dec 23. PMID: 36562210
28. Çetin A, Kaynar L, Kocyigit I, Hacioglu SK, Saraymen R, Ozturk A, et al. Role of grape seed extract on methotrexate induced oxidative stress in rat liver. The American journal of Chinese medicine. 2008;36(05):861-72. doi: 10.1142/S0192415X08006302. PMID: 19051353
29. Cetinkaya A, Bulbuloglu E, Kurutas EB, Kantarceken B. N-acetylcysteine ameliorates methotrexate-induced oxidative liver damage in rats. Med Sci Monit. 2006;12(8):BR274-BR8. Epub 2006 Jul 12. PMID: 16865059
30. Chabra A, Shokrzadeh M, Naghshvar F, Salehi F, Ahmadi A. Melatonin ameliorates oxidative stress and reproductive toxicity induced by cyclophosphamide in male mice. Hum Exp Toxicol. 2014;33(2):185-95. doi: 10.1177/0960327113489052. Epub 2013 May 23. PMID: 23703819
31. Winterbourn CC. Are free radicals involved in thiol-based redox signaling? Free Radic Biol Med. 2015;80:164-70. doi: 10.1016/j.freeradbiomed.2014.08.017. Epub 2014 Sep 30. PMID: 25277419
32. Selvakumar E, Prahalathan C, Mythili Y, Varalakshmi P. Mitigation of oxidative stress in cyclophosphamide-challenged hepatic tissue by DL-α-lipoic acid. Mol Cell Biochem. 2005;272(1):179-85. doi: 10.1007/s11010-005-7322-4. PMID: 16010986
33. Haque R, Bin-Hafeez B, Parvez S, Pandey S, Sayeed I, Ali M, et al. Aqueous extract of walnut (Juglans regia L.) protects mice against cyclophosphamideinduced biochemical toxicity. Hum Exp Toxicol. 2003;22(9):473-80. doi: 10.1191/0960327103ht388oa. PMID: 14580007
34. Maheshwari RA, Balaraman R, Sailor GU, Sen DB. Protective effect of simvastatin and rosuvastatin on trinitrobenzene sulfonic acid-induced colitis in rats. Indian J Pharmacol. 2015;47(1):17-21. doi: 10.4103/0253-7613.150311. PMID: 25821305
35. Qasim S, Alamgeer, Kalsoom S, Shahzad M, Bukhari IA, Vohra F, et al. RETRACTED: Rosuvastatin Attenuates Rheumatoid Arthritis-Associated Manifestations via Modulation of the Pro-and Anti-inflammatory Cytokine Network: A Combination of In Vitro and In Vivo Studies. ACS omega. 2021;6(3):2074-84. doi: 10.1021/acsomega.0c05054. eCollection 2021 Jan 26. PMID: 33521447
36. Fan W-C, Huang C-C, Yang Y-Y, Lin A, Lee K-C, Hsieh Y-C, et al. Serum pentraxin-3 and tumor necrosis factor-like weak inducer of apoptosis (TWEAK) predict severity of infections in acute decompensated cirrhotic patients. Journal of microbiology, immunology and infection. 2017;50(6):905-14. doi: 10.1016/j.jmii.2015.12.006. Epub 2016 Jan 18. PMID: 26872435
37. Şener G, Ekşioğlu-Demiralp E, Çetiner M, Ercan F, Yeğen BÇ. β-glucan ameliorates methotrexate-induced oxidative organ injury via its antioxidant and immunomodulatory effects. Eur J Pharmacol. 2006;542(1-3):170-8. doi: 10.1016/j.ejphar.2006.02.056. Epub 2006 May 17. PMID: 16793036
38. Fox JG, Feng Y, Theve EJ, Raczynski A, Fiala JL, Doernte AL, et al. Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut. 2010;59(01):88-97. doi: 10.1136/gut.2009.183749. PMID: 19850960
39. Rogers AB. Distance burning: how gut microbes promote extraintestinal cancers. Gut microbes. 2011;2(1):52-7. doi: 10.4161/gmic.2.1.14761. PMID: 21637019
40. Roderburg C, Luedde T. The role of the gut microbiome in the development and progression of liver cirrhosis and hepatocellular carcinoma. Gut microbes. 2014;5(4):441-5. doi: 10.4161/gmic.29599. Epub 2014 Jul 9. PMID: 25006881
41. Ponziani FR, Bhoori S, Castelli C, Putignani L, Rivoltini L, Del Chierico F, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology. 2019;69(1):107-20. doi: 10.1002/hep.30036. Epub 2018 Jul 10. PMID: 29665135